Blog

Stephen V. Liu Shares Phase II Data on First-Line Cisplatin, Irinotecan, and Durvalumab in SCLC

Stephen V Liu/X

Jun 30, 2025, 06:24

Stephen V. Liu Shares Phase II Data on First-Line Cisplatin, Irinotecan, and Durvalumab in SCLC

Stephen V Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X about a recent paper shared by Motoko Tachihara et al. published in Lung Cancer Journal:

“Phase II study of 1L cisplatin + irinotecan + durvalumab as for SCLC reported Lung Cancer Journal. PFS 5.7m with 1y PFS rate 19%. OS 16.9m with 1y OS 66%. RR 66%. G3+ AEs in 74%, 5% pneumonitis. Actuve but hard to interpret single arm phase II studies.”

Title: Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L)

Authors: Motoko Tachihara, Hiroyasu Shoda, Yuki Akazawa, Takayo Ota, Masahide Oki, Yuki Sato, Shunichi Sugawara, Satoshi Ikeda, Toshihide Yokoyama, Hiroyasu Kaneda, Shoichi Itoh, Akihiro Bessho, Nobuyuki Katakami, Satoshi Morita, Kazuhiko Nakagawa, Isamu Okamoto, Nobuyuki Yamamoto

Read Full Article.

An impactful insight featuring Small Cell Lung Cancer.

Other posts featuring Stephen V. Liu.

Akihiro Bessho cancer Hiroyasu Kaneda Hiroyasu Shoda Isamu Okamoto Kazuhiko Nakagawa Lung cancer Lung Cancer Journal Masahide Oki Motoko Tachihara Nobuyuki Katakami Nobuyuki Yamamoto OncoDaily Oncology Satoshi Ikeda Satoshi Morita SCLC Shoichi Itoh Shunichi Sugawara Stephen V Liu Takayo Ota Toshihide Yokoyama Yuki Akazawa Yuki Sato

Garo Armen Shares a Personal Story Driving Agenus' Mission in Cancer Care

Dr. Oliver Bogler, PhD: Leaving the National Cancer Institute

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care

Sibylle Loibl: Final survival Results from the PENELOPE-B trial published in Annals of Oncology

Yvonne Awards 2025: Honoring Global Oncology Leaders at ASCO’s Most Inspiring Night